HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elhalel, M. D. Articles by Tykocinski, M. L. Search for Related Content PubMed PubMed Citation Articles by Elhalel, M. D. Articles by Tykocinski, M. L.

CTLA-4 · FasL Induces Alloantigen-Specific Hyporesponsiveness¹

Michal Dranitzki Elhalel^2,*, Jui-Han Huang^*, William Schmidt^*, Jacob Rachmilewitz and Mark L. Tykocinski^3,*

^* Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; and Goldin Saval Institute, Hebrew University-Hadassah Medical School, Jerusalem, Israel

The APC:T cell interface can be effectively targeted with immunotherapeutic proteins. We previously described a unique trans signal converter protein, CTLA-4 · Fas ligand (FasL), that has the inherent capacities to tether the T cell inhibitor FasL (CD95 ligand) to the surfaces of B7 (CD80 and CD86)-positive APC (via CTLA-4:B7 interaction), and in so doing, to simultaneously interfere with B7-to-CD28 T cell activation signals. Given the continuing need for agents capable of inducing allograft tolerance without generalized immunosuppression, we have explored in depth the functional activity of CTLA-4 · FasL in human allogeneic MLR. CTLA-4 · FasL inhibits 1° MLR and induces specific hyporesponsiveness in 2° MLR, with both effects only partially reversible with exogenous IL-2. Moreover, the presence of exogenous IL-2 during the 1° MLR does not affect the induction of hyporesponsiveness upon restimulation. Furthermore, CTLA-4 · FasL enables partial activation of allostimulated T cells, reduces the fraction of actively dividing cells, and increases the percentage of dead cells among dividing T cells. Taken together, these findings suggest that CTLA-4 · FasL-mediated inhibition of secondary alloantigenic responses involves both anergy induction and clonal deletion. Thus, CTLA-4 · FasL, a paradigmatic trans signal converter protein, manifests unique functional properties and emerges as a potentially useful immunotherapeutic for modulating alloresponsiveness.

This article has been cited by other articles:

				M. Razmara, B. Hilliard, A. K. Ziarani, R. Murali, S. Yellayi, M. Ghazanfar, Y. H. Chen, and M. L. Tykocinski Fn14-TRAIL, a Chimeric Intercellular Signal Exchanger, Attenuates Experimental Autoimmune Encephalomyelitis Am. J. Pathol., February 1, 2009; 174(2): 460 - 474. [Abstract] [Full Text] [PDF]

				C. Schutz, M. Fleck, A. Mackensen, A. Zoso, D. Halbritter, J. P. Schneck, and M. Oelke Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells Blood, April 1, 2008; 111(7): 3546 - 3552. [Abstract] [Full Text] [PDF]

				A. Orbach, J. Rachmilewitz, M. Parnas, J.-H. Huang, M. L. Tykocinski, and M. Dranitzki-Elhalel CTLA-4 {middle dot} FasL Induces Early Apoptosis of Activated T Cells by Interfering with Anti-Apoptotic Signals J. Immunol., December 1, 2007; 179(11): 7287 - 7294. [Abstract] [Full Text] [PDF]

				M. Dranitzki-Elhalel, J. H. Huang, M. Sasson, J. Rachmilewitz, M. Parnas, and M. L. Tykocinski CD40{middle dot}FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism Int. Immunol., April 1, 2007; 19(4): 355 - 363. [Abstract] [Full Text] [PDF]